NCCN Guidelines for Patients® | Chronic Myelogenous Leukemia - page 29

29
NCCN Guidelines for Patients
®
: Chronic Myelogenous Leukemia
Version 1.2014
Par t 8
Par t 7
Par t 6
Par t 5
Par t 4
Par t 3
Par t 2
Par t 1
7
Par t 6
Par t 5
Par t 4
Par t 3
Par t 2
Par t 1
Definitions:
BCR-ABL
gene:
An
abnormal gene formed
when the
BCR
gene
and the
ABL
gene join
(fuse) together on the
Philadelphia chromosome
BCR-ABL protein:
A
protein that is made by the
abnormal
BCR-ABL
gene
and causes too many white
blood cells to be made
FDA:
A federal government
agency that regulates
drugs and food
Gene:
Set of coded
instructions in cells for
making and controlling cells
4.1 Tyrosine kinase inhibitor therapy
Table 4. TKI drugs used to treat CML
Generic name
Brand name (sold as)
Approved for
Imatinib
Gleevec
First-line treatment
Dasatinib
Sprycel
First-line treatment
Nilotinib
Tasigna
First-line treatment
Bosutinib
Bosulif
Second-line treatment
1...,19,20,21,22,23,24,25,26,27,28 30,31,32,33,34,35,36,37,38,39,...100
Powered by FlippingBook